BioCentury
ARTICLE | Finance

The barber's chairman

April 5, 1999 7:00 AM UTC

Ebb & Flow

Meanwhile,Anthra cited market conditions for withdrawing its NASDAQ IPO. The company is starting to generate royalty revenue, as partner Medeva launched Anthra's Valstar valrubicin in the U.S. in February to treat carcinoma in situ of the bladder. Anthra originally filed in March 1998 to sell 2.4 million shares at $9.50-$11.50, and then upped the deal to 2.7 million shares last May...